Skip to content


Open Access

NO/cGMP signalling in platelets

BMC Pharmacology20099(Suppl 1):P62

Published: 11 August 2009


Protein KinaseThrombinFibrinogenPlatelet AggregationGranule Secretion


NO/cGMP-signalling is important for the inhibition of platelet aggregation. The cGMP dependent protein kinase I plays thereby the key role in the signal cascade of NO/cGMP. It is already known that the interaction of the cGKI substrate IRAG with the IP3RI is essential for the NO/cGMP dependent inhibition of platelet aggregation. To specify the relevance of IRAG signalling for platelet function, IRAG deficient murine mutants were analysed. Diverse agonists like thrombin, thromboxane A2 and collagen induced platelet aggregation and granule secretion.


In wild-type platelets the activation was inhibited by NO-donors and a cGMP-analogue whereas in IRAG-deficient platelets the inhibiting effect of NO/cGMP was almost abolished. Furthermore NO/cGMP dependent inhibition of agonist-induced activation of the fibrinogen receptor GPIIb/IIIa and the resulting fibrinogen binding was strongly reduced in IRAG deficient platelets compared to wild-type platelets.


These findings delineate the predominant physiological role of IRAG for the NO/cGMP dependent inhibition of platelet aggregation and granule secretion.

Authors’ Affiliations

Department of Pharmacology, University Regensburg, Germany


© Schinner and Schlossmann; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.